Filing Flows › Cytokinetics (CYTK) › Q2 2025
Cytokinetics (CYTK) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Cytokinetics (CYTK) reported revenue of $66.8M for the second quarter 2025 (Q2 2025), up 268-fold from a year earlier and up 42-fold from the quarter before. Operating margin was -167.0%, net loss $134M (201.2% of revenue).
Cytokinetics, Q2 2025: revenue $66.8M (268× year over year), operating margin -167.0%, net loss $134M, operating cash flow −$128M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $66.8M | 42× | 268× |
| Operating profit | −$112M | — | — |
| Net earnings | −$134M | — | — |
| Operating cash flow | −$128M | — | — |
What changed
Revenue was $66.8M in Q2 2025, up 26715% year over year and up 4129% from the previous quarter. License and Milestone Revenues was the largest line at 96% of revenue. Collaboration Revenues added $2.2M year over year (up 1108%), 3% of the total change.
Operating costs exceeded revenue by $111.5M, an operating margin of -167.0%. Total costs grew 37% against revenue growth of 26715%. The fastest-growing cost line was Research & development (+38%). The quarter ended with a net loss of $134.4M, narrower than the previous quarter's $161.4M loss.
Operating cash flow was −$128.2M. Non-cash charges added back $2.3M of depreciation and amortization and $27.5M of share-based compensation. Working capital and other items used $23.7M. Capital expenditures of $4.1M exceeded it, leaving free cash flow of −$132.4M.
Questions
What was Cytokinetics' revenue in the second quarter 2025?
Cytokinetics (CYTK) reported revenue of $66.8M for the second quarter 2025 (Q2 2025), up 268-fold from a year earlier and up 42-fold from the quarter before.
Was Cytokinetics profitable in the second quarter 2025?
Operating loss was $112M (-167.0% of revenue) and net loss $134M.
Source: Cytokinetics 10-Q on SEC EDGAR.